{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/ankylosing-spondylitis/management/confirmed-ankylosing-spondylitis/","result":{"pageContext":{"chapter":{"id":"3e6db8e8-b2dc-5a7a-9fe2-0a341c7c963d","slug":"confirmed-ankylosing-spondylitis","fullItemName":"Scenario: Confirmed ankylosing spondylitis","depth":2,"htmlHeader":"<!-- begin field fd0b3924-7474-4e2d-9178-b055fc2a2cfe --><h2>Scenario: Confirmed ankylosing spondylitis</h2><!-- end field fd0b3924-7474-4e2d-9178-b055fc2a2cfe -->","summary":"Covers what advice to give and the treatment, follow up, and referral of someone with confirmed ankylosing spondylitis.","htmlStringContent":"<!-- begin item a1927616-d692-402f-8c5d-2e5c687b7ede --><!-- begin field bd88d190-8c38-4a84-be41-acbd0086dfd7 --><p>From age 16 years onwards.</p><!-- end field bd88d190-8c38-4a84-be41-acbd0086dfd7 --><!-- end item a1927616-d692-402f-8c5d-2e5c687b7ede -->","topic":{"id":"228aa309-0970-5ae0-a937-1a670214e066","topicId":"0752afda-bf5b-48c4-b4af-e842f0a9b229","topicName":"Ankylosing spondylitis","slug":"ankylosing-spondylitis","lastRevised":"Last revised in May 2019","chapters":[{"id":"1318829b-e445-59f5-8079-ced63414cf7e","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"28658e82-53d5-5798-84bf-7e67cc233b06","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"bc7876cf-e413-557d-b763-1b8198ae3cb7","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"b83be00a-c774-50aa-b8be-a04912f19bd5","slug":"changes","fullItemName":"Changes"},{"id":"ecb29915-59e9-5752-9bbb-fc44515688b3","slug":"update","fullItemName":"Update"}]},{"id":"81161324-4d7b-5419-85a9-dae9f57fa83b","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"c127b8df-f565-5637-adb8-bafbfd767c40","slug":"goals","fullItemName":"Goals"},{"id":"091c0d27-63a5-548e-8f08-5bfb48e416a7","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"f9ca120c-2183-5429-9706-101fc20540e1","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"58752ac1-77db-5b74-8e2e-bf0081dd74fd","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ffa55c0b-7b3d-583c-8a67-f0372230cbf9","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"4c33c07f-65b3-572b-b4c0-1eecffd16191","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"f4a7a8d2-8847-5779-9892-e4867ecaacdd","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"8c9e7d3f-07eb-5b06-9f42-67f6c18e4ce2","slug":"definition","fullItemName":"Definition"},{"id":"64b026f5-a69f-5ef8-800d-7aee9ac65509","slug":"causes","fullItemName":"Causes"},{"id":"fc3d12c0-7b54-576d-ba75-e8570df23bf0","slug":"prevalence","fullItemName":"Prevalence"},{"id":"ff462ad5-64de-5366-801e-9806962bcf65","slug":"complications","fullItemName":"Complications"},{"id":"76129f0b-5489-511d-bc1d-565b990f4fb8","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"a54d37d1-407b-50c4-b5e8-c98891ee1e00","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"6a2b7eca-b47b-5a11-9909-91a6aea6835a","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"ea0d0799-6976-5240-92c5-4623f9074fda","slug":"investigations","fullItemName":"Investigations"},{"id":"58c6e66c-a8a5-56c9-8c47-7127807d9c73","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"5f2d8235-d927-54d7-bd0a-4ec15e3336b8","fullItemName":"Management","slug":"management","subChapters":[{"id":"0a3569b1-7ede-51ad-abdd-77173b02733e","slug":"suspected-ankylosing-spondylitis","fullItemName":"Scenario: Suspected ankylosing spondylitis"},{"id":"3e6db8e8-b2dc-5a7a-9fe2-0a341c7c963d","slug":"confirmed-ankylosing-spondylitis","fullItemName":"Scenario: Confirmed ankylosing spondylitis"}]},{"id":"b82cc559-18dd-500a-add0-dde6d8b59e63","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"76b292a6-865e-5dcd-9885-3e235e7664a4","slug":"oral-nsaids","fullItemName":"Oral NSAIDs"},{"id":"113dcc0f-4841-54a0-9101-a64009316e7c","slug":"proton-pump-inhibitors-ppis","fullItemName":"Proton pump inhibitors (PPIs)"},{"id":"52667269-49b0-5132-839c-67d58b9480db","slug":"paracetamol-codeine","fullItemName":"Paracetamol and codeine"}]},{"id":"59c2b871-f61e-5fb4-a894-cae5bdeda4bd","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"80288a50-5bef-5779-8bf9-7d8abf169080","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"932977c5-3d44-5c3b-8787-7de309af3820","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"eb5fa8b8-2845-567c-ab0a-2274329dfc51","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"c4153414-1fd0-5779-a348-78ee4ab85730","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"12b49dd2-6a18-5e19-8960-15901b6a91b7","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"83d1e8ec-8cac-5c4a-ac1b-758b9b2501bb","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"67d800ae-fb2a-559a-89de-a4813d740021","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"5f2d8235-d927-54d7-bd0a-4ec15e3336b8","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"5f4d0b2d-3aa5-5ef4-9e89-a2dea8a8cc61","slug":"advice","fullItemName":"Advice","depth":3,"htmlHeader":"<!-- begin field 05c6e5b7-66dd-4234-9f46-aa4000ef6bf3 --><h3>What should I advise someone with confirmed ankylosing spondylitis?</h3><!-- end field 05c6e5b7-66dd-4234-9f46-aa4000ef6bf3 -->","summary":null,"htmlStringContent":"<!-- begin item e729bf9e-8c9f-4164-bae6-aa4000ef6b85 --><!-- begin field 09501f88-2652-4086-81cc-aa4000ef6bf3 --><ul><li><strong>Provide the person with information including:</strong><ul><li>An explanation of <a class=\"topic-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/background-information/definition/\">axial spondyloarthritis</a> and <a class=\"topic-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/background-information/definition/\">ankylosing spondylitis</a>. </li><li><a class=\"topic-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/background-information/prognosis/\">Prognosis</a> of ankylosing spondylitis.</li><li>Likely symptoms and their management.</li><li>Extra-articular symptoms (for example uveitis).</li><li>Flare episodes — consider a flare management plan tailored to the person's needs, preferences, and circumstances including access to care (for example specialist rheumatology nurse), self care (for example exercise, stretching), pain and fatigue management, potential medication changes, and managing the impact on work and daily life.</li><li>Treatment options (pharmacological and non-pharmacological) and their potential adverse effects — for example, advise people treated with TNF-alpha inhibitors that they may be at greater risk of skin cancer. </li><li>Self-help options, local support groups and charities — for example: <ul><li>The National Ankylosing Spondylitis Society (NASS) — offers information and guidance on managing axial spondyloarthritis and ankylosing spondylitis and the services available locally (<a data-hyperlink-id=\"c411fe2f-1674-432c-8078-aa4000f9c67a\" href=\"https://nass.co.uk/\">www.nass.co.uk</a>). It has produced an <a data-hyperlink-id=\"497b96a2-3ab9-468b-89d6-aa4d009e6e2c\" href=\"https://nass.co.uk/wp-content/uploads/resources/81955-NASS-Guidebook-for-Patients.pdf\">Axial spondyloarthritis and ankylosing spondylitis guidebook: answers and practical advice</a>.</li><li>Arthritis Care factsheet on <a data-hyperlink-id=\"1773e0ce-15f6-47df-b376-aa4d009e6e56\" href=\"https://www.arthritiscare.org.uk/assets/000/001/869/AnkylosingFactsheet_2017_update_original.pdf?1509978267\">Ankylosing spondylitis</a> (<a data-hyperlink-id=\"8e2c67d7-90f1-478d-8d86-aa4d009e6e69\" href=\"https://www.arthritiscare.org.uk/\">www.arthritiscare.org.uk</a>).</li><li>NHS information on <a data-hyperlink-id=\"7f66ab6b-e440-40ee-b45a-aa4d009e6e91\" href=\"https://www.nhs.uk/conditions/ankylosing-spondylitis/\">Ankylosing spondylitis</a> (<a data-hyperlink-id=\"0ab0ee7d-3c60-4843-afa0-aa4d009e6eab\" href=\"https://www.nhs.uk/\">www.nhs.uk</a>).</li></ul></li><li>Information about employment and the ability to work.</li></ul></li><li>Advise the person that they may be more prone to fractures and that they should seek medical advice following a fall or physical trauma, especially if they have increased pain.</li></ul><!-- end field 09501f88-2652-4086-81cc-aa4000ef6bf3 --><!-- end item e729bf9e-8c9f-4164-bae6-aa4000ef6b85 -->","subChapters":[{"id":"7c7c9190-505a-5753-8758-933bd66a65fc","slug":"basis-for-recommendation-5da","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 9520f2db-08e0-41cd-8f29-aa4000ef6bf8 --><h4>Basis for recommendation</h4><!-- end field 9520f2db-08e0-41cd-8f29-aa4000ef6bf8 -->","summary":null,"htmlStringContent":"<!-- begin item 5da67354-5217-4943-b56e-aa4000ef6bf8 --><!-- begin field c78f5e14-76ab-45f6-a6ed-aa4000ef6bf8 --><p>This recommendation is based on the National Institute for Health and Clinical Excellence (NICE) guideline <em>Spondyloarthritis in over 16s: diagnosis and management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">NICE, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">NICE, 2017b</a>]. </p><ul><li>The NICE guideline development group advocated information provision to improve clinical care and provide ongoing support. They felt that it is important for people diagnosed with spondyloarthritis to have access to individualised information to enable them to understand their condition, support them to make decisions about treatment and self-management, and contact an appropriate person within the multidisciplinary team if needed (for example if they have a flare) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">NICE, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">NICE, 2018</a>]. </li></ul><!-- end field c78f5e14-76ab-45f6-a6ed-aa4000ef6bf8 --><!-- end item 5da67354-5217-4943-b56e-aa4000ef6bf8 -->","subChapters":[]}]},{"id":"69c223dc-5f16-59d3-a538-5b2513cddee5","slug":"treatment","fullItemName":"Treatment","depth":3,"htmlHeader":"<!-- begin field 2fe51706-21b8-4151-ab0c-22c47afab631 --><h3>How should I manage uncontrolled symptoms?</h3><!-- end field 2fe51706-21b8-4151-ab0c-22c47afab631 -->","summary":null,"htmlStringContent":"<!-- begin item 1b2cd36c-69e3-43e9-9a85-72d067508b48 --><!-- begin field 15f9cf08-6dfb-498a-a21b-efee148fcdba --><ul><li><strong>Check compliance</strong> <strong>with, and tolerance to,</strong> exercise/stretching and current drug treatments.</li><li><strong>If the current nonsteroidal anti-inflammatory drug (NSAID) is ineffective,</strong> options to consider include:<ul><li>Seeking specialist advice.</li><li>Changing to another NSAID. </li><li>Adding additional analgesia (for example, paracetamol and/or codeine).</li></ul></li><li><strong>If the current NSAID is poorly tolerated:</strong><ul><li>See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/nsaids-prescribing-issues/\">NSAIDs - prescribing issues</a> for a discussion of the gastrointestinal and cardiovascular adverse effects of standard NSAIDs and coxibs and their management.  </li><li>Consider using an analgesic such as paracetamol or codeine (note that non-NSAID analgesics will not control inflammation).</li></ul></li><li><strong>Manage flares in primary care, or refer to specialist care, depending on the person's needs. </strong>Referral should be particularly considered for people who:<ul><li>Have recurrent or persistent flares.</li><li>Are taking biological DMARDs.</li><li>Have comorbidities that may affect treatment or management of flares.</li></ul></li><li><strong>If symptoms are poorly controlled despite appropriate treatment, </strong>refer for specialist rheumatology assessment or seek advice from the person's specialist. </li></ul><!-- end field 15f9cf08-6dfb-498a-a21b-efee148fcdba --><!-- end item 1b2cd36c-69e3-43e9-9a85-72d067508b48 -->","subChapters":[{"id":"aeaa6154-5ea4-5ee1-93c6-be61c1b9c11a","slug":"basis-for-recommendation-998","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field bec5f707-afe4-4f3e-ac7c-adff2bab946b --><h4>Basis for recommendation</h4><!-- end field bec5f707-afe4-4f3e-ac7c-adff2bab946b -->","summary":null,"htmlStringContent":"<!-- begin item 998807e5-87a5-4b0f-a7f6-248b40db239a --><!-- begin field b29e4971-983a-42f8-8f27-a47148411c5b --><h5>Checking compliance with existing treatments</h5><ul><li>This recommendation is pragmatic and based on what CKS considers to be good clinical practice.</li></ul><h5>Ineffective or poorly tolerated NSAID</h5><ul><li><strong>Seeking specialist advice</strong><ul><li>Experts agree that axial spondyloarthritis is usually diagnosed and its management coordinated by rheumatologists as it requires multidisciplinary management [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Taurog et al, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">van der Heijde et al, 2017</a>]. </li></ul></li><li><strong>Changing to another nonsteroidal anti-inflammatory drug (NSAID)</strong><ul><li>CKS has based this recommendation on the NICE guideline <em>Spondyloarthritis in over 16s: diagnosis and management</em> that advises 'if an NSAID taken at the maximum tolerated dose for 2–4 weeks does not provide adequate pain relief, consider switching to another NSAID' [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">NICE, 2017a</a>]. This also reflects Canadian management recommendations for spondyloarthritis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Rohekar et al, 2015</a>]. </li><li>The NICE guideline development group were of the opinion that if one NSAID did not produce a full response, another one may be effective and noted the common clinical practice of switching NSAIDs [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">NICE, 2017b</a>]. The recommendation is also extrapolated from<strong> </strong>the current clinical pathway for the pharmacological management of axial symptoms in people with spondyloarthritis that requires people to have tried at least two NSAIDs before progressing to biological DMARDs [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">NICE, 2017b</a>]. <ul><li>A Cochrane systematic review (search date June 2014) on NSAIDs for axial spondyloarthritis identified 3 studies (n = 669) in which no significant differences between NSAID classes in terms of benefits or harms were found. The authors suggested cardiovascular, gastrointestinal, and renal risks of NSAIDs should be considered when prescribing [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Kroon et al, 2015</a>]. </li></ul></li></ul></li><li><strong>Paracetamol and other analgesics</strong><ul><li>This recommendation reflects the ASAS-EULAR and Canadian management recommendations for spondyloarthritis (based on expert opinion). Despite a lack of formal evidence, they suggest analgesics (for example paracetamol and opioid-[like] drugs) might be considered for residual pain if other recommended treatments are contraindicated, poorly tolerated, or have failed [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Rohekar et al, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">van der Heijde et al, 2017</a>]. </li></ul></li></ul><h5>Management of flares</h5><ul><li>CKS has based this recommendation on the NICE guideline <em>Spondyloarthritis in over 16s: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">NICE, 2017a</a>]. </li></ul><h5>Referral or specialist advice if symptoms are poorly controlled</h5><ul><li>This recommendation is pragmatic and is based on what CKS considers to be good clinical practice. Experts agree that axial spondyloarthritis is usually diagnosed and its management coordinated by rheumatologists as it requires multidisciplinary management [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Taurog et al, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">van der Heijde et al, 2017</a>].  </li><li>Interventions that rheumatologists can use to control symptoms include:<ul><li><strong>Injection of corticosteroids.</strong> ASAS-EULAR recommendations state that glucocorticoid injections directed locally to the site of musculoskeletal inflammation may be considered, although it is acknowledged that evidence is lacking [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">van der Heijde et al, 2017</a>]. North American guidelines conditionally recommend local administration of parenteral glucocorticoids for adults with ankylosing spondylitis who, despite NSAID treatment, have isolated active sacroiliitis or stable axial disease and enthesitis or peripheral arthritis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Ward et al, 2016</a>]. Canadian management recommendations for spondyloarthritis state that corticosteroid injections at local sites of inflammation may be considered [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Rohekar et al, 2015</a>]. </li><li><strong>Biological DMARDs.</strong> These are an option for people with high disease activity despite other treatments [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Rohekar et al, 2015</a>]; anti-TNF therapy reduces disease activity and spinal pain in axial spondyloarthritis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">BSR and BHPR, 2017</a>]. A Cochrane systematic review found moderate to high quality evidence that anti-tumour necrosis factor (TNF) agents improve clinical symptoms (for example pain and function) in people with ankylosing spondylitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Maxwell et al, 2015</a>]. Choice takes into account comorbidities (including infection risk and previous malignancy). Options for severe ankylosing spondylitis in adults who have not responded to, or cannot tolerate NSAIDs include adalimumab, certolizumab pegol, etanercept, golimumab and infliximab. NICE suggests treatment with another TNF-alpha inhibitor if a person is unable to tolerate, or is unresponsive to treatment with a first TNF-alpha inhibitor [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">NICE, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">NICE, 2017b</a>]. DMARDs such as sulphasalazine and methotrexate are generally not effective for treating axial spondyloarthritis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Rohekar et al, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Sieper and Poddubnyy, 2017</a>].  </li><li><strong>Surgical methods</strong> may improve symptoms and reduce pain in people with spinal hyperkyphosis or severe hip involvement [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Kiltz et al, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">van der Heijde et al, 2017</a>]. </li></ul></li></ul><!-- end field b29e4971-983a-42f8-8f27-a47148411c5b --><!-- end item 998807e5-87a5-4b0f-a7f6-248b40db239a -->","subChapters":[]}]},{"id":"c1c743ad-2548-5d2a-b4a1-f705e6ab2cc0","slug":"follow-up","fullItemName":"Follow up","depth":3,"htmlHeader":"<!-- begin field b67e73ba-5d8c-4544-b5ed-b37e686589e7 --><h3>How should I follow-up a person with ankylosing spondylitis?</h3><!-- end field b67e73ba-5d8c-4544-b5ed-b37e686589e7 -->","summary":null,"htmlStringContent":"<!-- begin item c2459942-57bc-4f12-ba54-bb4f416fe7bb --><!-- begin field 48778530-6b52-4a2e-a4dc-09873be9bb5a --><ul><li><strong>Follow up is usually a shared care arrangement with the rheumatology service; local practices vary.</strong><ul><li>The frequency of monitoring should be decided by the rheumatologist in charge of management.</li><li>Follow up should monitor disease activity, progression, and response to treatment. This may include assessment of:<ul><li>Spinal movements.</li><li>Symptom control — for example pain, fatigue, morning stiffness and the presence of symptoms indicating hip arthritis, inflammatory arthritis in other joints, or enthesitis.</li><li>Extra-articular manifestations and <a class=\"topic-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/background-information/complications/\">complications</a>, particularly uveitis.</li><li>The impact of the condition on function and activities of daily living, including work.</li><li>Adverse effects of drugs (nonsteroidal anti-inflammatory drugs [NSAIDs] and biological DMARDs). Monitor people on long-term, regular NSAID treatment for changes in their gastrointestinal, cardiovascular and renal status.</li></ul></li></ul></li><li><strong>Ensure modifiable cardiovascular risk factors are managed if present </strong>(for example smoking, overweight, raised cholesterol, sedentary lifestyle, comorbidities). For more information on assessing and managing cardiovascular risk factors, see the CKS topics on:<ul><li><a class=\"topic-reference external-reference\" href=\"/topics/cvd-risk-assessment-management/\">CVD risk assessment and management</a>. </li><li><a class=\"topic-reference external-reference\" href=\"/topics/hypertension-not-diabetic/\">Hypertension - not diabetic</a> and <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-2/\">Diabetes - type 2</a>. </li><li><a class=\"topic-reference external-reference\" href=\"/topics/lipid-modification-cvd-prevention/\">Lipid modification - CVD prevention</a>. </li><li><a class=\"topic-reference external-reference\" href=\"/topics/obesity/\">Obesity</a>.</li><li><a class=\"topic-reference external-reference\" href=\"/topics/smoking-cessation/\">Smoking cessation</a>. </li></ul></li><li><strong>Ensure that a person with axial spondyloarthritis receives an assessment for osteoporosis every 2 years.</strong><ul><li>Be aware that bone mineral density measures may be elevated on spinal dual-energy X-ray absorptiometry (DEXA) due to the presence of syndesmophytes and ligamentous calcification, whereas hip measurements may be more reliable.</li></ul></li></ul><!-- end field 48778530-6b52-4a2e-a4dc-09873be9bb5a --><!-- end item c2459942-57bc-4f12-ba54-bb4f416fe7bb -->","subChapters":[{"id":"e691a325-4033-5526-aea7-e1c271f7cd3c","slug":"basis-for-recommendation-8ac","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 153dad2c-8a84-46de-8f42-567a7fc06fa2 --><h4>Basis for recommendation</h4><!-- end field 153dad2c-8a84-46de-8f42-567a7fc06fa2 -->","summary":null,"htmlStringContent":"<!-- begin item 8ac1008a-c079-4c5a-b773-c0eaab8684cc --><!-- begin field 9faa3532-719d-4cb5-a796-1289ca10a2ab --><h5>Shared care</h5><ul><li>Care provision varies between regions, with the decision to offer ongoing management in primary or secondary care dependent on the availability of appropriate knowledge and services<strong> </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">NICE, 2017b</a>]. </li></ul><h5>Frequency of monitoring</h5><ul><li>ASAS-EULAR management recommendations for axial spondyloarthritis indicate that the frequency of monitoring should be individualised based on symptoms, severity, and treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">van der Heijde et al, 2017</a>]. A previous version of these recommendations left the decision on frequency of monitoring to a person's rheumatologist on the basis that the disease course differs between patients [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Braun et al, 2011</a>]. </li></ul><h5>Monitoring disease activity, progression, and response to treatment</h5><ul><li>Evidence is lacking on strategies for monitoring disease activity and response [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Ward et al, 2016</a>], but experts advise that disease manifestations need to be monitored throughout the course of ankylosing spondylitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">NICE, 2017b</a>]. International recommendations suggest including patient-reported outcomes and clinical findings in disease monitoring of people with axial spondyloarthritis and use of validated disease activity measures for monitoring of ankylosing spondylitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Ward et al, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">van der Heijde et al, 2017</a>]. <ul><li>The recommendations to consider assessment of spinal movements, symptom control, extra-articular manifestations and complications, and the impact on function and activities of daily living are extrapolated from the clinical features and complications of ankylosing spondylitis, and are based on international consensus management recommendations for axial spondyloarthritis advising measuring disease activity on the basis of clinical signs and symptoms [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Smolen et al, 2018</a>], and what CKS considers to be good clinical practice. </li></ul></li><li>Experts suggest that ongoing monitoring of pharmacological treatments for people with spondyloarthritis can be undertaken in primary care [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">McAllister et al, 2017</a>]. Advice to take into account the potential adverse effects of drugs when monitoring is based on on the NICE guideline <em>Spondyloarthritis in over 16s: diagnosis and management </em>and Canadian treatment guidelines for spondyloarthritis, because the treatments used for spondyloarthritis can have adverse effects or lead to complications [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Rohekar et al, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">NICE, 2017b</a>].</li></ul><h5>Cardiovascular risk and osteoporosis assessment</h5><ul><li>These recommendations are based on the NICE guideline <em>Spondyloarthritis in over 16s: diagnosis and management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">NICE, 2017a</a>] and an evidence summary [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">BMJ Best Practice, 2018</a>]. The NICE guideline development group noted the importance of all complications, but were of the opinion that cardiovascular risk, osteoporosis, and fracture were the most key to monitor because of their frequency and potential severity in people with spondyloarthritis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">NICE, 2017b</a>].<ul><li>Cardiovascular risk may be elevated because of the systemic inflammatory nature of the spondyloarthritides, which can have direct vascular effects and negatively affect a person's ability to maintain their cardiovascular fitness [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">NICE, 2017b</a>]. Stopping smoking may have additional benefits for people with ankylosing spondylitis because there is an association between smoking and disease activity, functional outcomes, inflammation on MRI, and syndesmophyte formation, although there are no data demonstrating a positive effect of smoking cessation on signs and symptoms [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Rohekar et al, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">van der Heijde et al, 2017</a>]. <strong> </strong></li><li>Osteoporosis risk may be raised due to steroid use, but it is also part of the inflammatory process of spondyloarthritis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">NICE, 2017b</a>]. </li></ul></li></ul><!-- end field 9faa3532-719d-4cb5-a796-1289ca10a2ab --><!-- end item 8ac1008a-c079-4c5a-b773-c0eaab8684cc -->","subChapters":[]}]},{"id":"7d4cc2b8-5111-5384-9067-8f5f6323ebe8","slug":"referral","fullItemName":"Referral","depth":3,"htmlHeader":"<!-- begin field faea1abe-52fb-49da-bc64-34b889b36d0a --><h3>When should I refer a person with ankylosing spondylitis?</h3><!-- end field faea1abe-52fb-49da-bc64-34b889b36d0a -->","summary":null,"htmlStringContent":"<!-- begin item de39ee47-9a84-45cf-9ac2-2e43284c06f1 --><!-- begin field a0da3b37-5fd7-4e49-bae7-916b972f5d7e --><ul><li><strong>Refer urgently (same day) to ophthalmology</strong> if anterior uveitis is suspected.<ul><li>Suspect uveitis if the person has eye pain, eye redness, sensitivity to light, or blurred vision. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/uveitis/\">Uveitis</a>.</li></ul></li><li><strong>Refer (with urgency appropriate to the clinical situation) to a specialist</strong> (for example orthopaedics) if: <ul><li>Vertebral fracture is suspected — sudden occurrence of new neck or back pain even in the absence of trauma.</li><li>There is refractory hip pain or disability in association with structural damage on x-ray — hip arthroplasty may be considered.</li><li>The person has severe or progressive deformity of the spine (despite non-surgical treatment) that is significantly affecting their quality of life — spinal corrective osteotomy may be considered.</li></ul></li><li><strong>Urgently refer to, or seek advice from, rheumatology</strong> people treated with a tumour necrosis factor- (TNF) alpha inhibitor if a serious adverse effect is suspected (for example, infection, immunosuppression, or malignancy).</li><li><strong>Seek advice from the person's rheumatologist</strong> if symptoms are uncontrolled despite appropriate treatment.</li><li>If not already arranged by secondary care:<ul><li>Refer all people to physiotherapy for an individualised, structured exercise programme (including stretching, strengthening, and postural exercises and range of motion exercises for the lumbar, thoracic, and cervical spine).</li><li>Consider referral for hydrotherapy to manage pain or improve function.</li><li>Consider referral to a specialist therapist (for example physiotherapist, occupational therapist) for an assessment and advice on physical aids if the person has difficulty with everyday activities.</li></ul></li></ul><!-- end field a0da3b37-5fd7-4e49-bae7-916b972f5d7e --><!-- end item de39ee47-9a84-45cf-9ac2-2e43284c06f1 -->","subChapters":[{"id":"37290d57-abbe-59bd-a40b-4745ac66a2d9","slug":"basis-for-recommendation-c74","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 938c6e42-3dd6-4b1c-aea7-59a167775c6d --><h4>Basis for recommendation</h4><!-- end field 938c6e42-3dd6-4b1c-aea7-59a167775c6d -->","summary":null,"htmlStringContent":"<!-- begin item c745f0dc-a821-43f7-b743-a296bbb2c364 --><!-- begin field 875805bf-4532-4b1b-903b-b242d6c998b7 --><h5>Referral to ophthalmology if anterior uveitis is suspected</h5><ul><li>This recommendation reflects the National Institute for Health and Care Excellence (NICE) guidance <em>Spondyloarthritis in over 16s: diagnosis and management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">NICE, 2017a</a>]. The NICE guideline development group acknowledged the need for urgent ophthalmological assessment of people presenting with anterior uveitis in order to prevent potential sight damage [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">NICE, 2017b</a>]. </li></ul><h5>Referral to a specialist for suspected vertebral fracture, refractory hip pain or disability, or spinal deformity</h5><ul><li>This recommendation reflects the National Institute for Health and Care Excellence guidance <em>Spondyloarthritis in over 16s: diagnosis and management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">NICE, 2017a</a>], ASAS-EULAR recommendations for axial spondyloarthritis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">van der Heijde et al, 2017</a>], and expert opinion in a review article on ankylosing spondylitis and axial spondyloarthritis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Taurog et al, 2016</a>].</li></ul><h5>Referral if a serious adverse effect of TNF-alpha inhibitor treatment is suspected</h5><ul><li>This recommendation is extrapolated from a NICE evidence summary, listing infection, immunosuppression, and malignancy among the complications of biological DMARD treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">NICE, 2017b</a>]. A Cochrane systematic review of TNF-alpha inhibitors for ankylosing spondylitis noted that recognized adverse effects of anti‐TNF‐alpha therapy include serious infections such as tuberculosis, allergic reactions and autoimmune reactions [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Maxwell et al, 2015</a>].</li></ul><h5>Seeking advice if symptoms are uncontrolled despite appropriate treatment</h5><ul><li>This recommendation is pragmatic and is based on what CKS considers to be good clinical practice. Experts agree that axial spondyloarthritis is usually diagnosed and its management coordinated by rheumatologists as it requires multidisciplinary management [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Taurog et al, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">van der Heijde et al, 2017</a>]. </li><li>Interventions that rheumatologists can use to control symptoms include:<ul><li><strong>Injection of corticosteroids </strong>— ASAS-EULAR recommendations state that glucocorticoid injections directed locally to the site of musculoskeletal inflammation may be considered, although it is acknowledged that evidence is lacking [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">van der Heijde et al, 2017</a>]. North American guidelines conditionally recommend local administration of parenteral glucocorticoids for adults with ankylosing spondylitis who, despite NSAID treatment, have isolated active sacroiliitis or stable axial disease and enthesitis or peripheral arthritis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Ward et al, 2016</a>]. Canadian management recommendations for spondyloarthritis state that corticosteroid injections at local sites of inflammation may be considered [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Rohekar et al, 2015</a>]. </li><li><strong>Biological DMARDs</strong> — these are an option for people with high disease activity despite other treatments [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Rohekar et al, 2015</a>]; anti-TNF therapy reduces disease activity and spinal pain in axial spondyloarthritis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">BSR and BHPR, 2017</a>]. A Cochrane systematic review found moderate to high quality evidence that anti tumour necrosis factor (TNF) agents improve clinical symptoms (for example pain and function) in people with ankylosing spondylitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Maxwell et al, 2015</a>]. Choice takes into account comorbidities (including infection risk and previous malignancy). Options for severe ankylosing spondylitis in adults who have not responded to, or cannot tolerate NSAIDs include adalimumab, certolizumab pegol, etanercept, golimumab and infliximab. NICE suggests treatment with another TNF-alpha inhibitor if a person is unable to tolerate, or is unresponsive to treatment with a first TNF-alpha inhibitor [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">NICE, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">NICE, 2017b</a>]. DMARDs such as sulphasalazine and methotrexate are generally not effective for treating axial spondyloarthritis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Rohekar et al, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Sieper and Poddubnyy, 2017</a>].</li><li><strong>Surgical methods</strong> may improve symptoms and reduce pain in people with spinal hyperkyphosis or severe hip involvement [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Kiltz et al, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">van der Heijde et al, 2017</a>]. </li></ul></li></ul><h5>Referral for specialist therapies</h5><ul><li>These recommendations reflect advice in the NICE guideline <em>Spondyloarthritis in over 16s: diagnosis and management </em>on non-pharmacological management [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">NICE, 2017a</a>]. They are also consistent with Canadian treatment recommendations for the management of spondyloarthritis that state nonpharmacological treatment should include regular exercise, ideally with an experienced physiotherapist [<a class=\"bibliography-reference internal-reference\" href=\"/topics/ankylosing-spondylitis/references/\">Rohekar et al, 2015</a>].</li></ul><!-- end field 875805bf-4532-4b1b-903b-b242d6c998b7 --><!-- end item c745f0dc-a821-43f7-b743-a296bbb2c364 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}